Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

10/27/2021 | 08:30pm EST

WuXi Biologics announced that it has completed a remote GMP inspection by Health Canada for its drug substance facility (MFG2) in Wuxi city. There were no observations during the inspection, demonstrating that the company's premier quality system is in full compliance with global regulatory requirements. The comprehensive inspection was conducted by three inspectors and covered the facility's quality processes and entire production system. So far, WuXi Biologics has successfully completed nearly 20 regulatory inspections conducted by eight different agencies including the U.S. FDA, EMA and NMPA, 13 of which were conducted this year.


© S&P Capital IQ 2021
All news about WUXI BIOLOGICS (CAYMAN) INC.
03:52aHong Kong shares end marginally higher ahead of Fed policy update
RE
01/18WUXI BIOLOGICS CAYMAN : Completes GMP Inspection by South Korea's Ministry of Food and Dru..
PU
01/12WUXI BIOLOGICS CAYMAN : 40th Annual J.P. Morgan Healthcare Conference Presentation (in PDF..
PU
01/11Hong Kong shares close unchanged; Fed policy in focus
RE
01/11China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up
RE
01/06WUXI BIOLOGICS CAYMAN : Vaccines and BravoBio Sign Letter of Intent for Long-Term Collabor..
PU
01/05China stocks fall after hawkish Fed minutes; property, consumption drop
RE
01/05Wuxi Biologics Repurchases Nearly $503 Million Worth of Shares; Shares Fall 7%
MT
2021Hong Kong shares inch up in thin trade, healthcare jumps
RE
2021WUXI BIOLOGICS CAYMAN : and ImmuneOncia Sign MOU for Development and Manufacturing of Anti..
PU
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2021 9 752 M 1 536 M 1 536 M
Net income 2021 3 040 M 479 M 479 M
Net cash 2021 5 598 M 882 M 882 M
P/E ratio 2021 89,5x
Yield 2021 -
Capitalization 273 B 43 139 M 42 941 M
EV / Sales 2021 27,4x
EV / Sales 2022 18,7x
Nbr of Employees 7 686
Free-Float -
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 64,69 CNY
Average target price 126,46 CNY
Spread / Average Target 95,5%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-13.88%46 306
CSL LIMITED-11.13%88 334
SAMSUNG BIOLOGICS CO.,LTD.-16.17%43 094
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.47%32 656
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-13.37%27 201